The landscape of clinical trials is undergoing a profound transformation, one that holds the promise of faster drug development, increased patient participation, and improved data quality. At the forefront of this revolution stands the concept of Decentralised Clinical Trials (DCTs), a game-changing approach that is reshaping the way we conduct clinical research. In this blog […]
Fatigue is the sort of subjective phenomenological experience that has plagued philosophers and neuroscientists for centuries. For those with lived experience, fatigue can be debilitating, and patients can be left feeling ignored and maligned. Despite over 17 million people across Europe1, reporting symptoms of Long Covid, with fatigue being the most common symptom, there is
A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.
Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.
The latest advances in the treatment of Alzheimer’s disease and how Cambridge Cognition are designing and implementing empirically validated and clinically-relevant cognitive tasks to help develop the next generation of Alzheimer’s disease treatments.
There are presently over 140 drugs being explored as possible treatments for Alzheimer’s Disease (AD) in clinical trials. Of these, nearly 80% are intended to slow the progression of AD. Historically, cholinesterase inhibitor drugs such as galantamine, rivastigmine and donepezil have been approved for treatment of AD. These drugs have been shown to mitigate symptoms of AD, such as memory loss, however they are unable to treat the underlying neurobiological cause of the condition. As such, these drugs do not slow AD progression and are not considered a long-term solution in the battle to end the most common form of neurodegenerative disease.
The headline from this year’s AAIC in Amsterdam is undoubtedly the announcement of the results of TRAILBLAZER-ALZ-2, a phase 3 trial of Eli Lilly’s new drug Donanemab with 1,800 participants. Donanemab is an antibody-based drug that works by breaking down already-formed amyloid plaques that build up in Alzheimer’s disease (AD), rather than interfering with their production.
Insights Back to resource centre 6 October 2022 Understanding the effect of ashwagandha root extract on stress, sleep and cognition We caught up with Shefali Thanawala from Nutriventia Ltd who told us how CANTAB™ helped them to investigate the effects of Ashwagandha root extract on memory and focus in healthy, stressed adults. About Nutriventia, Ltd.Nutriventia Limited is the dietary supplements
Improvements and personalisation of research and treatment in schizophrenia and psychosis-related disorders; observations from Schizophrenia International Research Society (SIRS) 2023 conference.
Insights Back to resource centre 31 May 2023 Improvements and personalisation of research and treatment in schizophrenia and psychosis-related disorders; observations from Schizophrenia International Research Society (SIRS) 2023 conference. Earlier this month we had the pleasure of attending the Schizophrenia International Research Society (SIRS) conference in Toronto, Canada. We were delighted to present our recent findings from our meta-analysis comparing
Improvements and personalisation of research and treatment in schizophrenia and psychosis-related disorders; observations from Schizophrenia International Research Society (SIRS) 2023 conference. Read More »
Insights Back to resource centre 24 April 2023 Measuring cognition in areas outside of the Central Nervous System CANTAB® cognitive assessments are often used to measure cognition in disorders of the Central Nervous System, but did you know that they are also used in research that don’t involve the CNS? Here, two research teams explain how CANTAB is supporting their
Insights Back to resource centre 4 April 2023 Speech phenotypes in cognitively healthy participants at risk of developing Alzheimer’s disease This poster was presented at AD/PD in March 2023 and represents collaborative work between Winterlight Labs and Novartis. Poster SummaryChanges to speech patterns have been identified as early signs of Alzheimer’s Disease (AD) and have been shown to progress with
Insights Back to resource centre 21 March 2023 Using CANTAB to understand more about depth of anaesthesia and post-operative cognitive dysfunction We caught up with Anders Aasheim from Oslo University Hospital who told us more about his team’s research in understanding the effect of anaesthesia on cognitive function. My name is Anders Aasheim, and I am a nurse anaesthetist and